RECRUITING

ATATcH Alternating Treatment Plans for Advanced Cancer

Talk to us

Conditions

Head and Neck CancerLung CancerImmunotherapyChemotherapyPembrolizumab

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.

Official Title

Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH)

Quick Facts

Study Start:2022-04-28
Study Completion:2025-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05358548

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Missak Haigentz, MD
CONTACT
732-235-6031
mh1472@cinj.rutgers.edu

Principal Investigator

Missak Haigentz, MD
PRINCIPAL_INVESTIGATOR
Rutgers Cancer Institute of New Jersey

Study Locations (Sites)

Trinitas Hospital and Comprehensive Cancer Center
Elizabeth, New Jersey, 07207
United States
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, 08690
United States
RWJBarnabas Health - Jersey City
Jersey City, New Jersey, 07304
United States
RWJBarnabas Health - Monmouth Medical Center Southern Campus
Lakewood, New Jersey, 08701
United States
RWJBarnabas Health - Saint Barnabas Medical Center
Livingston, New Jersey, 10457
United States
RWJBarnabas Health - Monmouth Medical Center
Long Branch, New Jersey, 07740
United States
RWJ Barnabas Health - Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08901
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
United States
RWJBarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, 07112
United States
Robert Wood Johnson Somerset Hospital
Somerville, New Jersey, 08876
United States
RWJBarnabas Health - Community Medical Center
Toms River, New Jersey, 08755
United States

Collaborators and Investigators

Sponsor: Rutgers, The State University of New Jersey

  • Missak Haigentz, MD, PRINCIPAL_INVESTIGATOR, Rutgers Cancer Institute of New Jersey

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-04-28
Study Completion Date2025-12-01

Study Record Updates

Study Start Date2022-04-28
Study Completion Date2025-12-01

Terms related to this study

Keywords Provided by Researchers

  • Lung Cancer
  • Head and Neck Cancer
  • Immunotherapy
  • Chemotherapy
  • Pembrolizumab

Additional Relevant MeSH Terms

  • Head and Neck Cancer
  • Lung Cancer